The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysis

Cheng, Zhoujing; He, Lin; Guo, Yingjie; Song, Yuhua; Song, Shasha; Zhang, Lijiu

doi:10.1186/s12957-020-02017-0

Table 1 Characteristics of the eligible studies

From: The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysis

Study	Study type	Original nation	Period	Follow-up frequency, weeks	No. of patients	Median age, years^a	Follow-up, months^b	Medication in TACE	Initial sorafenib administration	Trail
Hoffmann et al. [24]	RCT	Germany	NR	NR	Combination, 24	58.5	33	Carboplatin	400 mg bid	24
Hoffmann et al. [24]	RCT	Germany	NR	NR	TACE, 26	58.0	33	Carboplatin	400 mg bid	24
Kudo et al. [26]	RCT	Japan	2006–2009	8	Combination, 138	69	NR	NR	400 mg bid	26
Kudo et al. [26]	RCT	Japan	2006–2009	8	TACE, 187	69	NR	NR	400 mg bid	26
Lencioni et al. [27]	RCT	USA	NR	8	Combination, 154	64.5	9	DEB-TACE	400 mg bid	27
Lencioni et al. [27]	RCT	USA	NR	8	TACE, 153	63	9	DEB-TACE	400 mg bid	27
Lee et al. [29]	RCT	China, Taiwan	2009–2010	4–8	Combination, 36	62.3	NR	NR	400 mg bid	29
Lee et al. [29]	RCT	China, Taiwan	2009–2010	4–8	TACE, 36	62.6	NR	NR	400 mg bid	29
Sansonno et al. [30]	RCT	Italy	2007–2011	2–4	Combination, 31	73	NR	Doxorubicin-based	400 mg bid	30
Sansonno et al. [30]	RCT	Italy	2007–2011	2–4	TACE, 31	72.8	NR	Doxorubicin-based	400 mg bid	30
Meyer et al. [35]	RCT	UK	2010–2015	6–12	Combination, 157	65	20.7	DEB-TACE	400 mg bid	35
Meyer et al. [35]	RCT	UK	2010–2015	6–12	TACE, 156	68	20.7	DEB-TACE	400 mg bid	35
Hu et al. [12]	Retrospective	China	2009–2013	6–8	Combination, 82	NR	6.9	Cisplatin-based	400 mg bid	12
Hu et al. [12]	Retrospective	China	2009–2013	6–8	TACE, 164	NR	6.9	Cisplatin-based	400 mg bid	12
Zhu et al. [14]	Retrospective	China	2010–2012	4–6	Combination, 46	48.4	11.3	Doxorubicin-based	400 mg bid	14
Zhu et al. [14]	Retrospective	China	2010–2012	4–6	TACE, 45	51.9	11.3	Doxorubicin-based	400 mg bid	14
Qu et al. [18]	Retrospective	China	2008–2011	6–8	Combination, 45	51	NR	Epirubicin-based	200 mg bid	18
Qu et al. [18]	Retrospective	China	2008–2011	6–8	TACE, 45	49	NR	Epirubicin-based	200 mg bid	18
Wu et al. [19]	Retrospective	China	2004–2014	4–8	Combination, 56	47.6	NR	Doxorubicin-based	400 mg bid	19
Wu et al. [19]	Retrospective	China	2004–2014	4–8	Sorafenib, 48	50.2	NR	Doxorubicin-based	400 mg bid	19
Tan et al. [20]	Retrospective	China	2004–2009	4–8	Combination, 10	46.3	NR	NR	400 mg bid	20
Tan et al. [20]	Retrospective	China	2004–2009	4–8	TACE, 10	43.4	NR	NR	400 mg bid	20
Bai et al. [21]	Retrospective	China	2004–2009	6	Combination, 82	54	1	Doxorubicin-based	400 mg bid	21
Bai et al. [21]	Retrospective	China	2004–2009	6	TACE, 146	52	1	Doxorubicin-based	400 mg bid	21
Lee et al. [22]	Retrospective	Korea	2000–2011	6–12	TACE, 26	58.3	NR	NR	NR	22
Lee et al. [22]	Retrospective	Korea	2000–2011	6–12	Sorafenib, 52	57.3	NR	NR	NR	22
Nishikawa et al. [23]	Retrospective	Japan	2004–2011	8–12	TACE, 55	67.9	NR	Epirubicin-based	200 mg bid	23
Nishikawa et al. [23]	Retrospective	Japan	2004–2011	8–12	Sorafenib, 56	69.1	NR	Epirubicin-based	200 mg bid	23
Ren et al. [25]	Retrospective	China	2008–2015	6–8	Combination, 61	NR	NR	Oxaliplatin-based	400 mg bid	25
Ren et al. [25]	Retrospective	China	2008–2015	6–8	TACE, 247	NR	NR	Oxaliplatin-based	400 mg bid	25
Arizumi et al. [28]	Retrospective	Japan	2008–2013	4–16	Combination, 32	73	NR	Epirubicin-based	400 mg bid	28
Arizumi et al. [28]	Retrospective	Japan	2008–2013	4–16	TACE, 24	77	NR	Epirubicin-based	400 mg bid	28
Ha et al. [31]	Retrospective	Korea	2007–2010	4–6	Combination, 129	54.1	NR	NR	400 mg bid	31
Ha et al. [31]	Retrospective	Korea	2007–2010	4–6	Sorafenib, 293	55.9	NR	NR	400 mg bid	31
Wan et al. [32]	Retrospective	China	2007–2011	4–12	Combination, 245	NR	35.8	Epirubicin-based	400 mg bid	32
Wan et al. [32]	Retrospective	China	2007–2011	4–12	TACE, 245	NR	35.8	Epirubicin-based	400 mg bid	32
Yao et al. [33]	Retrospective	China	2009–2015	4–6	Combination, 19	45.32	2-56	NR	400 mg bid	33
Yao et al. [33]	Retrospective	China	2009–2015	4–6	TACE, 78	46.67	2-56	NR	400 mg bid	33
Wu et al. [34]	Retrospective	China	2009–2014	4–6	Combination, 30	NR	11.3	NR	400 mg bid	34
Wu et al. [34]	Retrospective	China	2009–2014	4–6	TACE, 31	NR	11.3	NR	400 mg bid	34
Ogasawara et al. [36]	Retrospective	Japan	2002–2011	8–16	Combination, 36	71	12.4	Epirubicin-based	400 mg bid	36
Ogasawara et al. [36]	Retrospective	Japan	2002–2011	8–16	TACE, 20	71	12.4	Epirubicin-based	400 mg bid	36
Yao et al. [37]	Retrospective	China	2011–2014	4–6	Combination, 50	56.5	13.9	Epirubicin-based	400 mg bid	37
Yao et al. [37]	Retrospective	China	2011–2014	4–6	TACE, 100	55.9	13.9	Epirubicin-based	400 mg bid	37
Zhao et al. [38]	Retrospective	China	2009–2012	NR	Combination, 202	53	15.1	Doxorubicin-based	400 mg bid	38
Zhao et al. [38]	Retrospective	China	2009–2012	NR	TACE, 404	56	15.1	Doxorubicin-based	400 mg bid	38
Varghese et al. [39]	Retrospective	India	2010–2014	12–16	Combination, 37		NR	7	Doxorubicin-based	200 mg bid	39
Varghese et al. [39]	Retrospective	India	2010–2014	12–16	Sorafenib, 28		NR	7	Doxorubicin-based	200 mg bid	39
Zhu et al. [40]	Retrospective	China	2010–2014	12	Combination, 40		55.5	63.0	Doxorubicin-based	400 mg bid	40
Zhu et al. [40]	Retrospective	China	2010–2014	12	TACE, 66		54.1	63.0	Doxorubicin-based	400 mg bid	40
Peng et al. [41]	Retrospective	China	2010–2015	4–8	Combination, 106		56.5	15.6	Epirubicin-based	400 mg bid	41
Peng et al. [41]	Retrospective	China	2010–2015	4–8	Sorafenib, 101		56.3	15.6	Epirubicin-based	400 mg bid	41
Pinter et al. [42]	Retrospective	Austria	1999–2009	8–16	TACE, 34		NR	8.0	DEB-TACE	400 mg bid	42
Pinter et al. [42]	Retrospective	Austria	1999–2009	8–16	Sorafenib, 63		NR	8.0	DEB-TACE	400 mg bid	42
Zhang et al. [43]	Retrospective	China	2009–2013	4–8	Combination, 45		50.1	7.3	Epirubicin-based	400 mg bid	43
Zhang et al. [43]	Retrospective	China	2009–2013	4–8	Sorafenib, 44		53.6	7.3	Epirubicin-based	400 mg bid	43
Lei et al. [44]	Retrospective	China	2009–2011	NR	Combination, 38		52	23	Oxaliplatin-based	400 mg bid	44
Lei et al. [44]	Retrospective	China	2009–2011	NR	TACE, 29		51	23	Oxaliplatin-based	400 mg bid	44
Zheng et al. [45]	Retrospective	China	2008–2013	NR	Combination, 12		53	12.7	NR	200 mg bid	45
Zheng et al. [45]	Retrospective	China	2008–2013	NR	TACE, 10		53	12.7	NR	200 mg bid	45
Muhammad et al. [46]	Retrospective	USA	2007–2011	NR	Combination, 13		61.4	23	DEB-TACE	200 mg bid	46
Muhammad et al. [46]	Retrospective	USA	2007–2011	NR	TACE, 30		59.2	23	DEB-TACE	200 mg bid	46

Abbreviations: NR not reported in the text, RCT randomised controlled trial, OS overall survival, TTP time to progression, ORR overall response rate, DPR disease progression rate, TACE transarterial chemoembolization, DEB-TACE drug-eluting beads transarterial chemoembolization
^aSign indicates mean; otherwise, data are expressed as median
^bSign indicates median

Back to article page

ISSN: 1477-7819

Contact us

General enquiries: journalsubmissions@springernature.com

World Journal of Surgical Oncology

Contact us